Konstantinos Xynos, M.D., serves as the Chief Medical Officer at Replimune Group Inc., a clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies for the treatment of cancer. Dr. Xynos brings a wealth of experience in oncology and clinical development to his role at Replimune. He has been instrumental in advancing the company's pipeline of innovative therapies, including RP1, RP2, and RP3, which are being evaluated in various clinical trials for the treatment of solid tumors. Prior to joining Replimune, Dr. Xynos held several key positions in the biopharmaceutical industry. He served as the Vice President of Clinical Development at Agenus Inc., where he played a pivotal role in the development of novel immuno-oncology therapies. Before that, he worked at Merck & Co., Inc., where he contributed to the development of Keytruda (pembrolizumab), a groundbreaking immunotherapy that has transformed the treatment landscape for multiple cancer types. Dr. Xynos's extensive experience in clinical development and his deep understanding of the immuno-oncology field have been invaluable assets to Replimune. As Chief Medical Officer at Replimune, Dr. Xynos is responsible for overseeing the company's clinical development strategy and execution. He leads a team of dedicated professionals in designing and conducting clinical trials to evaluate the safety and efficacy of Replimune's oncolytic immunotherapies. Under his leadership, Replimune has made significant progress in advancing its clinical programs, with several promising results reported from ongoing trials. Dr. Xynos's vision and expertise continue to drive the company's mission to deliver transformative therapies to patients with cancer.